A PRODUCT FIT FOR THE MARKET:
Applikate runs on the vision of Yale pathologists & engineers
A fully-integrated pathology solution designed and tested at leading U.S. academic hospitals.
A competitor amid outdated technologies:
Applikate shifts the histopathology & technology paradigm
Applikate delivers modern approach to pathology: no slides, digitally native, and naturally collaborative.
A professional team for better returns:
Applikate combines business acumen & operational excellence
Our financial discipline and the strategic use of non-dilutive funds has led to an extended runway and greater shareholder value.
Recipient of multiple NIH awards
Validated by experts.
Applikate delivers a breakthrough device that captivates leading pathologists, academic hospitals, and venture capitalists.
Some Of Our Advisors
Intrinsically digital. Innately disruptive. Naturally collaborative.
Unlike all competitors, our platform is not constrained by archaic processes, grainy images, and artifacts. Physical slides may result in poor quality images which impede diagnostics and result in time-consuming and inaccurate results when deriving cell-type counts.
$ 0 million
in seed capital
$ 0 million
in NIH sponsored grants
0 U.S. patents
granted to the founders
with professional experience in medical device & health technology
Financial discipline and investor capital deployed on the highest business priorities.
Digital pathology improves upon traditional pathology by converting physical slides to images. Applikate eliminates slides altogether so images are immediately accessible without the cost of propping up old technology.
Unlike traditional pathology, Applikate's patented technology has no physical limitations. Once imaged the results are available for consultation or diagnosis.
As of 2022, Applikate has received $3.4 million in NIH sponsored grants, 3 issued U.S. patents, and $2.6 million in seed funding from 20 investors.